Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1965 1
1979 3
1981 10
1982 3
1983 12
1984 4
1985 11
1986 13
1987 10
1988 15
1989 27
1990 25
1991 26
1992 23
1993 37
1994 28
1995 42
1996 45
1997 50
1998 77
1999 69
2000 73
2001 86
2002 100
2003 154
2004 196
2005 221
2006 244
2007 299
2008 343
2009 376
2010 448
2011 490
2012 616
2013 645
2014 711
2015 868
2016 905
2017 1031
2018 1167
2019 1249
2020 1568
2021 1724
2022 1919
2023 1809
2024 2085
2025 608

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,238 results

Results by year

Filters applied: . Clear all
Page 1
Approach to Myelopathy and Myelitis.
Douglas AG, Xu DJ, Shah MP. Douglas AG, et al. Among authors: xu dj. Neurol Clin. 2022 Feb;40(1):133-156. doi: 10.1016/j.ncl.2021.08.009. Neurol Clin. 2022. PMID: 34798966 Review.
Reply.
Momenaei B, Wakabayashi T, Shahlaee A, Durrani AF, Pandit SA, Wang K, Mansour HA, Abishek RM, Xu D, Sridhar J, Yonekawa Y, Kuriyan AE. Momenaei B, et al. Among authors: xu d. Ophthalmol Retina. 2024 Jan;8(1):e1-e2. doi: 10.1016/j.oret.2023.09.003. Epub 2023 Oct 9. Ophthalmol Retina. 2024. PMID: 37815785 No abstract available.
Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study.
Jin G, Lv J, Yang M, Wang M, Zhu M, Wang T, Yan C, Yu C, Ding Y, Li G, Ren C, Ni J, Zhang R, Guo Y, Bian Z, Zheng Y, Zhang N, Jiang Y, Chen J, Wang Y, Xu D, Zheng H, Yang L, Chen Y, Walters R, Millwood IY, Dai J, Ma H, Chen K, Chen Z, Hu Z, Wei Q, Shen H, Li L. Jin G, et al. Among authors: xu d. Lancet Oncol. 2020 Oct;21(10):1378-1386. doi: 10.1016/S1470-2045(20)30460-5. Lancet Oncol. 2020. PMID: 33002439
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Galle PR, et al. Among authors: xu dz. Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27. Lancet Oncol. 2021. PMID: 34051880 Clinical Trial.
CMTM6, a potential immunotherapy target.
Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B. Liang J, et al. Among authors: xu d. J Cancer Res Clin Oncol. 2022 Jan;148(1):47-56. doi: 10.1007/s00432-021-03835-9. Epub 2021 Nov 16. J Cancer Res Clin Oncol. 2022. PMID: 34783871 Review.
18,238 results
You have reached the last available page of results. Please see the User Guide for more information.